JOINCARE PHARMACEUTICAL GROUP INDUSTRY CO.,LTD.

Joincare Pharmaceutical Group Industry Co.,Ltd.

600380

CNE000001816

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
12 ^CNY	+0.08%		+3.27%	-3.46%

Apr. 25	Joincare Pharmaceutical Group Industry Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 18	Joincare Pharma Says Flu Drug Phase 3 Trial Attains Primary Endpoint	MT

Joincare Pharmaceutical Group Industry Co.,Ltd.'s Equity Buyback announced on February 11, 2020, has expired with 19,890,613 shares, representing 1.03% for CNY 253.61 million.

July 11, 2020

The company expired its plan on July 12, 2020.

Latest news about Joincare Pharmaceutical Group Industry Co.,Ltd.

Joincare Pharmaceutical Group Industry Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Joincare Pharma Says Flu Drug Phase 3 Trial Attains Primary Endpoint	Apr. 18	MT
Joincare Pharmaceutical Successfully Completes TG-1000 Phase III Study	Apr. 17	CI
Joincare Pharmaceutical Group's 2023 Profit Falls 4%; Shares Slide 4%	Apr. 02	MT
Joincare Pharmaceutical Group Industry Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
Livzon Pharma to Trial JP-1366 Tablets as Reflux Esophagitis Drug	Feb. 23	MT
Livzon Pharmaceutical Appoints Former Joincare Exec as Vice President	Jan. 30	MT
Boan Biotechnology, Joincare Sign Exclusive License Deal for Respiratory Disease Treatment	Jan. 29	MT
Shandong Boan Biotechnology Co., Ltd. Enters into Agreement with Joincare Pharmaceutical Group Industry Co., Ltd	Jan. 26	CI
Joincare Pharmaceutical, Guangzhou Fermion Technology Get Nod to Trial Analgesic Drug	Jan. 12	MT
Livzon Pharmaceutical to Continue Getting Services from Joincare Pharmaceutical	Jan. 02	MT
Joincare Pharma’s 210 Drugs Included in China's Medical Insurance Catalog	Dec. 14	MT
Joincare Gets Nod to Trial Pain Relief Drug	Dec. 05	MT
Joincare Pharma Shortlisted For China’s Drug Procurement Program	Nov. 06	MT
Tranche Update on Joincare Pharmaceutical Group Industry Co.,Ltd.'s Equity Buyback Plan announced on December 15, 2022.	23-10-30	CI
Joincare Pharmaceutical Group Industry Co.,Ltd.'s Equity Buyback announced on December 15, 2022 has closed with 49,706,643 shares, representing 2.61% for CNY 599.91 million.	23-10-26	CI
Joincare Pharmaceutical Group Industry Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Joincare Pharma Unit Gets Go Signal from China for Phase 3 Trial of Endometriosis Drug	23-10-17	MT
Tranche Update on Joincare Pharmaceutical Group Industry Co.,Ltd.'s Equity Buyback Plan announced on December 15, 2022.	23-10-09	CI
Joincare Pharmaceutical Group Industry Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
Livzon Pharmaceutical Gets Nod to Register Blonanserin Tablets	23-08-14	MT
Joincare Pharma's Unit Gets Nod for COVID-19 Vaccine Trial	23-07-17	MT
Tranche Update on Joincare Pharmaceutical Group Industry Co.,Ltd.'s Equity Buyback Plan announced on December 15, 2022.	23-07-03	CI
Joincare Pharma Unit Gets Nod for Anti-Bacterial Drug	23-06-08	MT
Joincare Pharmaceutical Group Industry Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI

Chart Joincare Pharmaceutical Group Industry Co.,Ltd.

Duration

Period

Chart Joincare Pharmaceutical Group Industry Co.,Ltd.

More charts

Joincare Pharmaceutical Group Industry Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals and healthcare products. The Company's products include chemical materials and intermediates, chemical agents, health products, traditional Chinese medicines, diagnostic reagents and equipment. The Company is also engaged in electricity business. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-28 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Joincare Pharmaceutical Group Industry Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12 CNY

Average target price

14.31 CNY

Spread / Average Target

+19.25%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JOINCARE PHARMACEUTICAL GROUP INDUSTRY CO.,LTD.	-3.46%	3.09B
ELI LILLY AND COMPANY	+25.83%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.76%	354B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+3.00%	296B
ASTRAZENECA PLC	+13.09%	233B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.26%	144B

Other Pharmaceuticals